OrbiMed’s Aclaris Therapeutics ACRS Stock Holding History

OrbiMed’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Buy	+421,500	New	+$1.88M	0.04%	118
2023 Q1	–	Sell	-2,758,434	Closed	-$43.4M	–	125
2022 Q4	$43.4M	Hold	2,758,434	–	–	0.83%	45
2022 Q3	$43.4M	Buy	2,758,434 +432,934	+19%	+$6.82M	0.81%	46
2022 Q2	$32.5M	Buy	2,325,500 +745,600	+47%	+$10.4M	0.59%	54
2022 Q1	$27.2M	Buy	1,579,900 +594,000	+60%	+$8.1M	0.44%	57
2021 Q4	$14.3M	Buy	985,900 +334,117	+51%	+$5.06M	0.18%	101
2021 Q3	$11.7M	Buy	651,783 +289,783	+80%	+$4.65M	0.13%	119
2021 Q2	$6.36M	Buy	+362,000	New	+$8.22M	0.06%	142

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

OrbiMed's ACRS Position: Q2 2026 in Review

OrbiMed opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 421,500 shares worth $2.23M. The stake represents 0.04% of the portfolio and ranks #118 among its holdings. This is a return to the name: OrbiMed previously reported a position in ACRS as recently as Q4 2022.

OrbiMed first reported a position in ACRS in Q2 2021 and has held it in 8 quarters since. The position peaked at $43.4M in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

OrbiMed held 421,500 shares of Aclaris Therapeutics worth $2.23M as of Q2 2026.
Aclaris Therapeutics was a new OrbiMed position in Q2 2026.
Aclaris Therapeutics made up 0.04% of OrbiMed's portfolio in Q2 2026, its #118 holding.
OrbiMed first reported a position in Aclaris Therapeutics in Q2 2021 and has held it in 8 quarters since.
OrbiMed's Aclaris Therapeutics position peaked at $43.4M in Q4 2022.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.